Tummers Willemieke S, Willmann Juergen K, Bonsing Bert A, Vahrmeijer Alexander L, Gambhir Sanjiv S, Swijnenburg Rutger-Jan
Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Pancreas. 2018 Jul;47(6):675-689. doi: 10.1097/MPA.0000000000001075.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. To improve outcomes, there is a critical need for improved tools for detection, accurate staging, and resectability assessment. This could improve patient stratification for the most optimal primary treatment modality. Molecular imaging, used in combination with tumor-specific imaging agents, can improve established imaging methods for PDAC. These novel, tumor-specific imaging agents developed to target specific biomarkers have the potential to specifically differentiate between malignant and benign diseases, such as pancreatitis. When these agents are coupled to various types of labels, this type of molecular imaging can provide integrated diagnostic, noninvasive imaging of PDAC as well as image-guided pancreatic surgery. This review provides a detailed overview of the current clinical imaging applications, upcoming molecular imaging strategies for PDAC, and potential targets for imaging, with an emphasis on intraoperative imaging applications.
胰腺导管腺癌（PDAC）的预后很差。为了改善治疗结果，迫切需要改进检测、准确分期和可切除性评估的工具。这可以改善患者分层，以选择最优化的主要治疗方式。分子成像与肿瘤特异性成像剂联合使用，可以改进现有的PDAC成像方法。这些针对特定生物标志物开发的新型肿瘤特异性成像剂有可能特异性地区分恶性疾病和良性疾病，如胰腺炎。当这些试剂与各种类型的标记物结合时，这种分子成像可以提供PDAC的综合诊断、非侵入性成像以及图像引导的胰腺手术。本综述详细概述了当前的临床成像应用、即将出现的PDAC分子成像策略以及成像的潜在靶点，重点是术中成像应用。
